Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma

Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. Clinical data of patients with SCLC and MPM who were treated wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-09, Vol.172, p.357-366
Hauptverfasser:	Dumoulin, Daphne W., Cantini, Luca, Cornelissen, Robin, Vink, Madelief, Klaase, Larissa, Slooff, Kick, Tebayna, Nura, Mankor, Joanne M., Baart, Sara J., Hendriks, Rudi, Dingemans, Anne-Marie C., Willemsen, Marcella, Aerts, Joachim G.J.V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carbolines CD4 antigen CD8 antigen CD8-Positive T-Lymphocytes - metabolism Cell proliferation Depletion Disease control Flow cytometry Heterocyclic Compounds, 4 or More Rings Humans immune monitoring Immune system Immunomodulation Immunotherapy Lung cancer Lung Neoplasms - pathology Lurbinectedin Lymphocytes Lymphocytes T malignant pleural mesothelioma/MPM Mesothelioma Mesothelioma - drug therapy Mesothelioma, Malignant Monocytes Natural killer cells Patients Peripheral blood Pleural Neoplasms - drug therapy Pleural Neoplasms - pathology Safety management small cell lung cancer/SCLC Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!